BioStem Technologies Inc (OTC:BSEM) Stock Continues To Trend Higher: What’s The Buzz?
There were some companies which had come into sharp focus yesterday and one of those was BioStem Technologies Inc (OTC:BSEM), which saw its stock clock gains of 18% amidst significant interest. The rally was triggered by a major new announcement from the company on Tuesday.
Nationwide Product Launch
Yesterday BioStem Technologies announced that it would commence the nationwide launch of its product Vendaje AC in collaboration with Venture Medical LLC, its exclusive marketing and sales partner. In the news release, it was also revealed that the launch would begin in the fourth fiscal quarter of the year and would encompass all MAC (Medicare Administrative Contractor) regions in the United States.
Importance of the Launch
It was also stated in the news release that the launch was going to be a major new milestone for the company. The launch of the product would make it the second product from BioStem Technologies that would be available for Medicare reimbursement across the 50 states.
The nationwide launch of the product was also a demonstration of the commitment of the company in delivering advanced wound care solutions for patients afflicted with non-healing and chronic wounds, the company asserted. BioStem Technologies also expressed its excitement at the collaboration with Venture Medical, who had been pivotal in the successful launch of another of its products, AminoWrap2.
Key Quote
Jason Matuszewski, CEO of BioStem Technologies Inc., commented: “This is a pivotal moment for BioStem Technologies. With nationwide Medicare reimbursement, Vendaje AC® becomes our second product available to patients across all 50 states. The launch of Vendaje AC® underscores our commitment to delivering innovative wound care solutions for patients suffering from chronic, non-healing wounds. We’re excited to collaborate with Venture Medical once again, whose partnership was instrumental in the success of AmnioWrap2®. Together, we’re expanding access to cutting-edge treatments that make a real difference in patient outcomes.”
Technicals
| +/- EMA(20) | 15.39 (+34.18%) |
| +/- SMA(50) | 11.92 (+73.24%) |
| +/- SMA(200) | 9.97 (+107.12%) |
| 5-Day Perf. | +21.72% |
| 1-Month Perf. | +108.59% |
| 3-Month Perf. | +156.65% |
| 6-Month Perf. | +158.12% |
| YTD Perf. | +252.39% |
| 1-Year Perf. | +553.48% |
| RSI(14) | 85.03 |
| ATR(14) | 1.47 |
| ADX(14) | 39.19 |
| Beta (5Y) | 0.18 |
